Organization Profile

Related Organization(s)

You just read:

Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis

News provided by

Eli Lilly and Company

Sep 29, 2015, 06:45 ET